Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice

Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis

(2010) R. Fan et al.   DIABETES OBESITY & METABOLISM

Emerging roles for the TGFβ family in pancreatic β-cell homeostasis

(2010) Melissa L. Brown et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes

(2009) James Mu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors

(2009) E.J. Verspohl   PHARMACOLOGY & THERAPEUTICS

The Intersection of Safety and Adherence: New Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus

(2009) Barbara J Zarowitz et al.   PHARMACOTHERAPY

Targeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins

(2008) Marzieh Salehi et al.   ENDOCRINE REVIEWS

Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice

(2008) Yusuke Moritoh et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys

(2008) Bumsup Lee et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Protection of pancreatic beta-cells: Is it feasible?

(2007) Enzo Bonora   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES